Ozempic and Mounjaro: ‘King Kong’ of Weight Loss or a Hammer Swinging at Your Health?
Rabat – Smoking kills, so do other diseases, other challenges, and other issues that we either underestimate or are truly unaware of the dangers they pose, including obesity. In response to gaining weight, many people resort to quick methods to shed some pounds, including those influenced by social media trends. Other methods also include injections. […]
The GLP-1 Era Is Changing How We Think About Self Control
Although scientists are just beginning to study food noise as a concept, individuals who have taken a GLP-1 drug often report that it significantly reduces this distracting, ruminative thinking about food – a near-constant background hum of unwanted food-related thoughts, feelings and desires that may contribute to making poor food choices. – Psyche
STAT+: Pharmalittle: We’re reading about a Novo drug and Alzheimer’s, a Sarepta drug warning, and more
Hello, everyone, and how are you today? The skies over the Pharmalot campus are soggy this morning, but our spirits are sunny, nonetheless. After all, as the Morning Mayor liked to say: Every new day should be unwrapped like a precious gift. So while you tug on the ribbon, we will get busy gathering interesting […]
STAT+: Novo nears release of high-stakes data on Alzheimer’s and GLP-1s
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Today, we report on how lawsuits linked to Covid-19 are gaining prominence under the Trump administration. We also await Novo results on GLP-1 effects on Alzheimer’s, and more. The need-to-know this morning Alkermes increased […]
BellRing Brands, Inc. (NYSE:BRBR) Q4 2025 Earnings Call Transcript
BellRing Brands, Inc. (NYSE:BRBR) Q4 2025 Earnings Call Transcript November 18, 2025 BellRing Brands, Inc. misses on earnings expectations. Reported EPS is $0.51 EPS, expectations were $0.546. Operator: Good day, and thank you for standing by. Welcome to the BellRing Brands Fourth Quarter Fiscal Year 2025 Earnings Conference Call. [Operator Instructions] Please be advised today’s […]
Parsing the Rhetoric on ACA Subsidies
In a social media post, Republican Sen. Ron Johnson criticized Sen. Bernie Sanders, an independent, for wrongly saying that Affordable Care Act premiums would at least double for “over 20 million Americans” if enhanced subsidies expire. They would more than double on average, not for all of those 20 million people. Johnson glossed over the […]
Jefferson health plan losses drag down Q1 performance
Philadelphia-based Thomas Jefferson University, owner of Jefferson Health, reported an operating loss of $103.8 million (-2.5% operating margin) in the first quarter of fiscal 2026, including $19.4 million in restructuring costs, according to its Nov. 14 financial report. Restructuring costs for the three months ended Sept. 30 included employee severance and “other strategic actions to […]
Eli Lilly wants to be part of making a big dent in obesity and diabetes, says co’s India head Winselow Tucker
Eli Lilly India chief Winselow Tucker said the company’s strategy of combining a strong product with ecosystem partnerships and patient education has helped drive early momentum for Mounjaro in India, where the dual-action diabetes and obesity drug has clocked ₹450 crore in sales within seven months. He said India has a large unmet need, with […]
JCM, Vol. 14, Pages 8209: Real-World Effectiveness of Finerenone Added to SGLT2 Inhibitor and GLP-1 Receptor Agonist Therapy in Individuals with Type 2 Diabetes and Chronic Kidney Disease
JCM, Vol. 14, Pages 8209: Real-World Effectiveness of Finerenone Added to SGLT2 Inhibitor and GLP-1 Receptor Agonist Therapy in Individuals with Type 2 Diabetes and Chronic Kidney Disease Journal of Clinical Medicine doi: 10.3390/jcm14228209 Authors: Afif Nakhleh Khaled Khazim Naim Shehadeh Background/Objectives: Recent randomized controlled trial evidence in adults with type 2 diabetes (T2D) and […]
Novo Nordisk Rolls Out Lower Prices for Ozempic and Wegovy
WEDNESDAY, Nov. 19, 2025 — People paying out of pocket for Ozempic or Wegovy may soon see lower costs, as Novo Nordisk rolls out new price discounts for its popular GLP-1 medications.
The company announced that through the end of March…